Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes

Sexual Dimorphism in the Prevalence and Progression of Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes

Sex might interact with cardioautonomic neuropathy (CAN) in the development of macrovascular disease in patients with type 1 diabetes (T1D). The regulation of the autonomic system shows sexual dimorphism, and may contribute to the cardiovascular risk overload in women with T1D.

The aims of this project are:

A.1) Determining the prevalence of CAN and subclinical atherosclerosis in a large cohort of consecutive patients with T1D as a function of sex (cross-sectional study).

A.2.) Addressing the progression of CAN and subclinical atherosclerosis in patients with T1D as a function of sex (longitudinal prospective study).

A.3.) Investigating the influence of sex steroids and circulating biomarkers in the development and progression of CAN and subclinical atherosclerosis.

Research designs:

A cross-sectional design/prevalence screening study determining the prevalence of CAN as a function of sex in 320 consecutive individuals with DM1.

A longitudinal prospective study: the cohort of prevalence screening study will be prospectively followed, and the assessment of cardiovascular autonomic function and subclinical atherosclerosis will be repeated over time.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

320

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain, 28034
        • Lía Nattero Chávez

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Participants are selected from a consecutive cohort of individuals with T1D, who are regularly attending the outpatient clinic of the Diabetes Unit from Hospital Universitario Ramón y Cajal of Madrid.

Description

Inclusion Criteria:

- Diagnosis of type 1 diabetes mellitus, as defined by ADA criteria

Exclusion Criteria:

  • Renal transplantation or renal replacement therapy;
  • prior diagnosis of macrovascular disease (CHD, cerebrovascular disease, carotid disease, PAD, or atherosclerotic aortic aneurism);
  • ongoing pregnancy;
  • diagnosis of types of diabetes mellitus other than type 1;
  • diagnosis of types of neuropathy other than diabetic neuropathy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To address sexual dimorphism in the prevalence of CAN in patients with T1D.
Time Frame: Two years
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
Two years
To address sexual dimorphism in the prevalence of CAN in patients with T1D.
Time Frame: Two years
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
Two years
To address sexual dimorphism in subclinical atherosclerosis in patients with T1D.
Time Frame: Two years
Mean carotid intima-media thickness (mm)
Two years
To assess the role of sex on the progression of cardiovascular dysautonomy in patients with T1D.
Time Frame: Four years
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
Four years
To assess the role of sex on the progression of cardiovascular dysautonomy in patients with T1D.
Time Frame: Four years
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
Four years
To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.
Time Frame: Four years
Mean carotid intima-media thickness (mm)
Four years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To identify the influence of sex steroids on the evolution of cardiac autonomic dysfunction.
Time Frame: Four years
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
Four years
To identify the influence of sex steroids on the evolution of cardiac autonomic dysfunction.
Time Frame: Four years
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
Four years
To identify the influence of sex steroids on the evolution of subclinical atherosclerosis
Time Frame: Four years
Mean carotid intima-media thickness (mm)
Four years
To identify novel circulating markers of CAN
Time Frame: Four years
Heart rate responses (bpm) to active standing and Ewing and Clarke tests.
Four years
To identify novel circulating markers of CAN
Time Frame: Four years
Blood pressure (mmHg) to active standing and Ewing and Clarke tests.
Four years
To identify novel circulating markers of subclinical atherosclerosis
Time Frame: Four years
Mean carotid intima-media thickness (mm)
Four years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2018

Primary Completion (Actual)

August 1, 2025

Study Completion (Actual)

August 1, 2025

Study Registration Dates

First Submitted

May 30, 2021

First Submitted That Met QC Criteria

June 25, 2021

First Posted (Actual)

July 6, 2021

Study Record Updates

Last Update Posted (Actual)

August 7, 2025

Last Update Submitted That Met QC Criteria

August 5, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe